Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

December 10, 2025 02:47:27 pm

Source: SeekingAlpha

2025-12-10 14:47:27 ET

The last time I spoke about Denali Therapeutics Inc. ( DNLI ) it was with respect to a Seeking Alpha article entitled "Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains." With respect to this article, I went over that the company might still possibly have a path forward with respect to the development of its drug DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS]. That is, there might be a path forward on a biomarker analysis in 2025 for this drug candidate....

Read the full article on Seeking Alpha

For further details see:

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment